Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 0.75 |
| ▸ | EGFR | P00533 | 2/20 | 0.75 |
| ▸ | ITK | Q08881 | 2/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | TEC | P42680 | 1/20 | 0.75 |
| ▸ | TXK | P42681 | 1/20 | 0.75 |
| ▸ | BMX | P51813 | 1/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22593966 | 1.00 | BTK (1.00) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL24570594 | 1.00 | BTK (1.00) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL21378172 | 0.89 | BTK (0.84) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL21378174 | 0.89 | BTK (0.84) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL21378187 | 0.86 | BTK (1.00) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL20198766 | 0.86 | BTK (1.00) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL20198764 | 0.85 | BTK (0.77) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL20198763 | 0.85 | BTK (0.77) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL17866138 | 0.83 | BTK (0.71) | BTKBLKEGFRITKERBB2 | |
| SCHEMBL17866139 | 0.83 | BTK (0.71) | BTKBLKEGFRITKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-3546460-B1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-07-08 | — | — | EP | disclosed |
| EP-3546460-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-10-02 | — | — | EP | disclosed |
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-26 | — | — | US | disclosed |
| WO-2018095398-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | BTK, SYK, CDK8 | BTK 1/4885BLK 9/4885EGFR 1581/4885 |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | BTK, SYK, CDK8 | BTK 1/4885BLK 9/4885EGFR 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.